Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)

Clinical trial NCT06261125 · RECRUITING

Trial details

NCT number: NCT06261125
Sponsor: Mian XI
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma

Start date: 2024-03-10
Primary completion: 2026-06-30
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.